FIELD: medicine, pharmacy.
SUBSTANCE: invention refers to a compound of general formula
or pharmaceutically acceptable salt thereof. In formula (I) Cy represents phenyl, C3-8 cycloalkyl or C3-8 cycloalkenyl , Cya is a heterocyclic group with the structure given in the invention formula, R1a and R2b are groups defined in the formula. The objects of invention are also the pharmaceutical composition and the agent based on formula (I) compound, the method of diabetes treatment and prevention and compound application.
EFFECT: invention is SGLT1 inhibitor and can be used to treat or prevent diabetes.
24 cl, 4 tbl, 605 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | 2014 |
|
RU2671212C2 |
KINASE INHIBITORS | 2012 |
|
RU2623734C9 |
AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINE | 2017 |
|
RU2729069C1 |
INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
NOVEL PHOSPHATE COMPOUNDS, SYNTHESIS METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | 2014 |
|
RU2617682C2 |
DERIVATIVES OF AMINOMETHYLPYRROLIDINE WITH AROMATIC SUBSTITUTES | 2000 |
|
RU2255938C2 |
MACROCYCLIC COMPOUND AND ITS USE | 2019 |
|
RU2798235C2 |
DIAZOLE LACTAMS | 2013 |
|
RU2666730C2 |
TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNELS INHIBITOR | 2013 |
|
RU2645158C2 |
Authors
Dates
2017-04-26—Published
2012-08-30—Filed